A new report from The Scripps Research Institute in California has found a way to make cells resistant to HIV. Antibodies bind to cell receptors that block the virus from infecting it.
Read more
Category: biotech/medical – Page 2,749
New one from Liz.
Full Video ► https://goo.gl/tHvTF5
BioViva ► http://bioviva-science.com
Liz Parrish is the Founder and CEO of BioViva Sciences USA Inc. BioViva is committed to extending healthy lifespans using gene therapy. Liz is known as “the woman who wants to genetically engineer you,” she is a humanitarian, entrepreneur and innovator and a leading voice for genetic cures. As a strong proponent of progress and education for the advancement of gene therapy, she serves as a motivational speaker to the public at large for the life sciences. She is actively involved in international educational media outreach and sits on the board of the International Longevity Alliance (ILA). She is the founder of BioTrove Investments LLC and the BioTrove Podcasts which is committed to offering a meaningful way for people to learn about and fund research in regenerative medicine. She is also the Secretary of the American Longevity Alliance (ALA) a 501©(3) nonprofit trade association that brings together individuals, companies, and organizations who work in advancing the emerging field of cellular & regenerative medicine with the aim to get governments to consider aging a disease.
Parrish received two kinds of injections, which were administered outside the United States: a myostatin inhibitor, which is expected to prevent age-associated muscle loss; and a telomerase gene therapy, which is expected to lengthen telomeres, segments of DNA at the ends of chromosomes whose shortening is associated with aging and degenerative disease.
——-
This week saw researchers announce a promising new approach to Parkinson’s by the use of cellular reprogramming. The team lead by Ernest Arenas used a cocktail of four transcription factors to reprogram support cells inside the brain.
The research team placed the reprogramming factors into a harmless type of lentivirus and injected them en masse into a Parkinson’s disease model mice. The viruses infected support cells in the brain known as astrocytes (a support cell that regulates the transmission of electrical impulses within the brain) which are present in large numbers. The lentiviruses delivered their four factor payload to the target cells changing them from astrocytes into dopamine producing neurons.
Within three weeks the first cells had been reprogrammed and could be detected, and after fifteen weeks there were abundant numbers of dopamine producing neurons present. This is good news indeed as it also confirms that once reprogrammed the cells remain changed and stable and do not revert back into astrocytes.
Read more
Interest in rejuvenation biotechnology is growing rapidly and attracting investors.
- Jim Mellon has made an investment in Insilico Medicine to enable the company to validate the many molecules discovered using deep learning and launch multi-modal biomarkers of human aging
Monday, April 10, 2017, Baltimore, MD — Insilico Medicine, Inc, a big data analytics company applying deep learning techniques to drug discovery, biomarker development, and aging research today announced that it has closed an investment from the billionaire biotechnology investor Jim Mellon. Proceeds will be used to perform pre-clinical validation of multiple lead molecules developed using Insilico Medicine’s drug discovery pipelines and to advance research in deep learned biomarkers of aging and disease.
“Unlike many wealthy business people who rely entirely on their advisors to support their investment in biotechnology, Jim Mellon has spent a substantial amount of time familiarizing himself with recent developments in biogerontology. He does not just come in with the funding, but brings in expert knowledge and a network of biotechnology and pharmaceutical executives, who work very quickly and focus on the commercialization potential. We are thrilled to have Mr. Mellon as one of our investors and business partners”, said Alex Zhavoronkov, PhD, founder, and CEO of Insilico Medicine, Inc.
Read more
Everolimus heading for human clinical trials later this year to treat immune system decline.
The biotechnology company PureTech are moving towards human clinical trials with a new therapy that may slow down the aging process and combat age-related disease. The company has licensed two new drug candidates, derivatives of the drug Rapamycin, from pharmaceutical giant Novartis.
PureTech have recently announced a joint venture with Novartis called resTORbio and are moving to clinical trials of the new drugs later this year. The aim of the first test phase is to see if the new drug can rejuvenate the immune system of aged people a key reason why we lose the ability to resist diseases as we grow older.
Novartis already successfully completed two Phase IIa studies exploring the immune-enhancing potential of mTORC1 inhibitors in elderly patients. resTORbio plans to build on those findings and start a Phase IIb study with the two licensed candidates later this year. Excitingly the firm has also said that it plans to extend the program to other age-related disorders in the future.
Read more
For people in that area, and it may be worth while to try reaching out to them for funding for anti aging stuff.
Why is RAND opening a Bay Area office?
The San Francisco Bay Area is really at the center of technology and transformation. That’s also been a focus at RAND since our very first report, Preliminary Design of an Experimental World-Circling Spaceship, in 1946, which foretold the creation of satellites more than a decade before Sputnik.
Today, our researchers are working on important questions related to autonomous vehicles, drones, cybersecurity, education technology, virtual medicine—the same questions driving Silicon Valley startups and billion-dollar Bay Area corporations. At the same time, we’re looking at issues surrounding social inequality, drug policy, water resource management, and transportation, all of which directly relate to the Bay Area.
Read more
Technically, an animal could use RNA editing to change the nature of its proteins without completely altering the underlying DNA instructions. This makes the cephalopods’ ability to do it a very interesting phenomenon, but it’s unclear as to why the species requires this much RNA editing. Many of the edited proteins were found in the animals’ brains, which is why scientists think the editing and their brainpower could be linked.
More than any other species on earth, octopuses are particularly smart—they can solve puzzles, use tools, and communicate using color. Now scientists are saying they’re also capable of editing their RNA.
A team of scientists led by Joshua Rosenthal at the Marine Biological Laboratory and Noa Liscovitch-Braur and Eli Eisenberg at Tel Aviv University have discovered that octopuses and squid are capable of a type of genetic alteration called RNA editing. The process is rare among other species, leading scientists to believe that the cephalopods have evolved to follow a special kind of gene recoding.
Normally, living creatures use the information contained in DNA to make proteins, and RNA is the go-between, simply transmitting the message in the DNA. More than 60 percent of RNA transcripts in squid are recoded by editing, and similar levels of RNA editing were identified in other cephalopod species, including two octopuses and a cuttlefish. This changes the message that gets sent out, which in turn changes the proteins that get produced. In comparison, other species like fruit flies and humans experience recoding events only a fraction of one percent of the time. But exactly how the gene editing mechanics work is a mystery.
Read more
Some weird religious stories w/ transhumanism Expect the conflict between religion and transhumanism to get worse, as closed-minded conservative viewpoints get challenged by radical science and a future with no need for an afterlife: http://barbwire.com/2017/04/06/cybernetic-messiah-transhuman…elligence/ & http://www.livebytheword.blog/google-directors-push-for-comp…s-explain/ & http://ctktexas.com/pastoral-backstory-march-30th-2017/
By J. Davila Ashcroft
The recent film Ghost in the Shell is a science fiction tale about a young girl (known as Major) used as an experiment in a Transhumanist/Artificial Intelligence experiment, turning her into a weapon. At first, she complies, thinking the company behind the experiment saved her life after her family died. The truth is, however, that the company took her forcefully while she was a runaway. Major finds out that this company has done the same to others as well, and this knowledge causes her to turn on the company. Throughout the story the viewer is confronted with the existential questions behind such an experiment as Major struggles with the trauma of not feeling things like the warmth of human skin, and the sensations of touch and taste, and feels less than human, though she is told many times she is better than human. While this is obviously a science fiction story, what might comes as a surprise to some is that the subject matter of the film is not just fiction. Transhumanism and Artificial Intelligence on the level of the things explored in this film are all too real, and seem to be only a few years around the corner.
Recently it was reported that Elon Musk of SpaceX fame had a rather disturbing meeting with Demis Hassabis. Hassabis is the man in charge of a very disturbing project with far reaching plans akin to the Ghost in the Shell story, known as DeepMind. DeepMind is a Google project dedicated to exploring and developing all the possible uses of Artificial Intelligence. Musk stated during this meeting that the colonization of Mars is important because Hassabis’ work will make earth too dangerous for humans. By way of demonstrating how dangerous the goals of DeepMind are, one of its business partners, Shane Lange is reported to have stated, “I think human extinction will probably occur, and this technology will play a part in it.” Lange likely understands what critics of artificial intelligence have been saying for years. That is, such technology has an almost certain probability of become “self aware”. That is, becoming aware of its own existence, abilities, and developing distinct opinions and protocols that override those of its creators. If artificial intelligence does become sentient, that would mean, for advocates of A.I., that we would then owe them moral consideration. They, however, would owe humanity no such consideration if they perceived us as a danger to their existence, since we could simply disconnect them. In that scenario we would be an existential threat, and what do you think would come of that? Thus Lange’s statement carries an important message.
Already so-called “deep learning” machines are capable of figuring out solutions that weren’t programmed into them, and actually teach themselves to improve. For example, AlphaGo, an artificial intelligence designed to play the game Go, developed its own strategies for winning at the game. Strategies which its creators cannot explain and are at a loss to understand.
Transhumanist Philosophy The fact is many of us have been physically altered in some way. Some of the most common examples are lasik surgery, hip and knee replacements, and heart valve replacements, and nearly everyone has had vaccines that enhance our normal physical ability to resist certain illnesses and disease. The question is, how far is too far? How “enhanced” is too enhanced?